YI (111, Inc) Year-over-year earnings per share growth for the last 12 months

YI (111 Inc) - company brandmark

The development of a B2B digital drug distribution platform drives the operational scale of 111, Inc. (YI) in China. The current quarterly EPS pace confirms this growth, with the current level standing at -109.40. An extensive network of automated warehouses guarantees supply stability. Skilled IT personnel and logistics experts, motivated by the digitalization of healthcare, support process efficiency.

YI: 111 Inc Year-over-year net earnings per share growth for the last 12 months 07/04/2022 - 11/13/2026

YI (111, Inc.): analytical breakdowns and indicator data

- stock price and consensus target price:
Market Chart 111.com.cn|YI - Price Target Chart
- business market valuation indicators:
Market Capitalization 111, Inc.|YI - Enterprise Value
- company book value details:
Accounting Value per Share 111, Inc.|YI - Company Net Assets|Market Capitalization to Book Value 111.com.cn|YI - Cumulative Company Assets
- debt and liquidity data:
Debt to Capital 111, Inc.|YI - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient 111.com.cn|YI - Company Debts|Debts to Book Capitalization Ratio 111, Inc|YI - Company Long-Term Debts|Company Short-Term Loans and Borrowings 111, Inc.|Quick Ratio 111.com.cn
- earnings and valuation multiples information:
YI - Company Net Income|Expected Net Income 111, Inc.|YI - Price to Earnings Ratio|Projected Price to Earnings 111.com.cn|YI - PEG Multiple|EV/EBITDA Multiple 111, Inc.|YI - Operating profit EBITDA|Net earnings per share for the last 12 months 111, Inc.|YI - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months 111.com.cn|YI - Earnings growth in current year|Earnings growth forecast for next year 111, Inc.
Fundamental valuation:YI 111, Inc
Brand item of 111, Inc

The assessment of 111, Inc. (YI) margin of safety is based on the dynamics of net earnings per share, which measures the efficiency of capital generation for shareholders over a rolling quarter. By analyzing the trajectory of quarterly EPS growth, an investor can identify business stagnation caused by geopolitical pressure between the US and China, which restricts access to Western investments and complicates the logistics of imported pharmaceuticals.

Competitor analysis

cvshealth.com - Year-over-year net earnings per share change for the last twelve months|MCK (McKesson Corp) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months AmerisourceBergen (COR)|Quarterly EPS earnings growth Cardinal Health Group|Year-over-year net earnings per share growth for the last 12 months HSIC (Henry Schein, Inc.)|Year-over-year net earnings per share growth for the last 12 months prestigebrands.com PBH|Year-over-year net earnings per share change for the last twelve months WGRX|RDGT - Year-over-year net earnings per share growth for the last 12 months|UPC (Universe Pharmacy) - Earnings per share growth in annualized terms for the last twelve months|BDRX - Quarterly EPS earnings growth|9zt.hk - Year-over-year net earnings per share change for the last twelve months|BIMI (usbimi.com) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share trend for the last twelve months China Jo-Jo Drugstores Inc. CJJD|Quarterly EPS earnings growth Walgreens